Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06778408 · ClinicalTrials.gov registry record · Phase 2

Hybrid Arc Palliative Radiation Therapy (HART): A Single Arm Phase II Trial

A Phase 2 study of Metastatic Cancer (Different Solid Tumour Types) and Palliative Radiotherapy, sponsored by University of Vermont Medical Center.

Recruiting
Registry status
Phase 2
Development phase
103
Enrollment target
1
Study location

NCT06778408 is a Phase 2 study of Metastatic Cancer (Different Solid Tumour Types) and Palliative Radiotherapy that is actively recruiting participants, run by University of Vermont Medical Center. The registered enrollment target is 103 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06778408, a Phase 2 study of Metastatic Cancer (Different Solid Tumour Types) and Palliative Radiotherapy, is actively recruiting participants, sponsored by University of Vermont Medical Center.

RECRUITING
Registry status
Phase 2
Development phase
103 participants
Enrollment target
1
Study location

Study Summary

This is a prospective single-center single-arm Phase II trial of HART for patients with metastatic cancer. The primary objective is to assess the incidence of acute GI toxicity following HART. PRO-CTCAE GI scores observed in the study patients will be compared to historical rates. Secondary outcomes include measuring changes in health-related quality of life, esophageal quality of life, toxicity, dosimetric outcomes, and pain.

Interventions

  • RADIATION Hybrid Palliative Radiation Therapy

Study Locations (1)

Vermont

  • University of Vermont Medical Center - Burlington

Trial Details

FieldValue
Enrollment Target 103 participants
Start Date 2025-04-28
Est. Completion 2028-03
Phase Phase 2

What the Registry Record Tells You About NCT06778408

The ClinicalTrials.gov registry entry for NCT06778408 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Vermont Medical Center, which has 27 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Metastatic Cancer (Different Solid Tumour Types) appearing as the primary indexed condition, and to 1 intervention - of which Hybrid Palliative Radiation Therapy is the first listed.

NCT06778408 reports 1 study location spanning 1 distinct geographic area - top geographies include Vermont.

Frequently Asked Questions

What is clinical trial NCT06778408 about?

NCT06778408 is a clinical study titled "Hybrid Arc Palliative Radiation Therapy (HART): A Single Arm Phase II Trial". This is a prospective single-center single-arm Phase II trial of HART for patients with metastatic cancer. The primary objective is to assess the incidence of acute GI toxicity following HART. PRO-CTCAE GI scores observed in the study patients will be compared to historical rates. Secondary outcomes...

What is the current status of trial NCT06778408?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 103 participants. The study started on 2025-04-28. Estimated completion is 2028-03.

What conditions does trial NCT06778408 study?

This clinical trial studies the following conditions: Metastatic Cancer (Different Solid Tumour Types), Palliative Radiotherapy.

What interventions are being tested in trial NCT06778408?

The interventions under investigation include: Hybrid Palliative Radiation Therapy (RADIATION).

Who is sponsoring clinical trial NCT06778408?

This trial is sponsored by University of Vermont Medical Center, which has 27 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06778408 being conducted?

This trial has 1 study location across Vermont. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Metastatic Cancer (Different Solid Tumour Types)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.